Matrix Laboratories Limited, leading Hyderabad based pharmaceutical company, has received US Food & Drug Administration's (USFDA) tentative approval to manufacture and market Efavirenz; Emtricitabine and Tenofovir Disoproxil Fumarate Tablets.

The sources informed that the approval has been granted for tablets in potencies of 600 mg, 200 mg and 300 mg respectively.

Efavirenz (brand names Sustiva and Stocrin) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is prescribed for the treatment of a human immunodeficiency virus (HIV) type 1.

Emtricitabine (FTC), with trade name Emtriva (formerly Coviracil), is a nucleoside reverse transcriptase inhibitor (NRTI) which is used for treating HIV infection in adults and children.

Tenofovir disoproxil fumarate (TDF or PMPA[1]), marketed by Gilead Sciences under the trade name Viread, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people.